Literature DB >> 20096678

Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis.

Alok Kumar1, Lakshmi Bala, Jayantee Kalita, U K Misra, R L Singh, C L Khetrapal, G Nagesh Babu.   

Abstract

BACKGROUND: Amyotrophic lateral sclerosis (ALS), an invariably fatal neurological disorder shows complicated pathogenesis that poses challenges with respect to diagnosis as well as monitoring of disease progression.
METHODS: We investigated metabolite profiles in the serum of 30 patients with ALS, 10 patients of Hirayama disease, which served as a neurological disease control and 25 healthy controls by using (1) H NMR spectroscopy.
RESULTS: Compared to healthy controls, the ALS patients had higher quantities of glutamate (P<0.001), beta-hydroxybutyrate (P<0.001), acetate (P<0.01), acetone (P<0.05), and formate (P<0.001), and lower concentrations of glutamine (P<0.02), histidine (P<0.001) and N-acetyl derivatives. On the other hand, Hirayama disease patients had significantly higher median concentrations of pyruvate (P<0.05), glutamate (P<0.001), formate (P<0.05) and lower median concentrations of N-acetyl derivatives. Furthermore, we also found that serum glutamate showed a positive correlation (P<0.001, r=0.6487) whereas, histidine showed a negative correlation (P<0.001, r=-0.5641) with the duration of the disease in ALS.
CONCLUSIONS: Such (1) H NMR study of serum may reveal abnormal metabolite patterns, which could have the potential to serve as surrogate markers for monitoring ALS disease progression. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096678     DOI: 10.1016/j.cca.2010.01.016

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  31 in total

1.  ¹H NMR-based serum metabolic profiling in compensated and decompensated cirrhosis.

Authors:  Su-Wen Qi; Zhi-Guang Tu; Wu-Jian Peng; Lin-Xian Wang; Xin Ou-Yang; An-Ji Cai; Yong Dai
Journal:  World J Gastroenterol       Date:  2012-01-21       Impact factor: 5.742

Review 2.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

3.  The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism.

Authors:  Stephanos Pavlides; Aristotelis Tsirigos; Gemma Migneco; Diana Whitaker-Menezes; Barbara Chiavarina; Neal Flomenberg; Philippe G Frank; Mathew C Casimiro; Chenguang Wang; Richard G Pestell; Ubaldo E Martinez-Outschoorn; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2010-09-01       Impact factor: 4.534

Review 4.  Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  Lucas T Vu; Robert Bowser
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

5.  1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis.

Authors:  Hélène Blasco; Philippe Corcia; Caroline Moreau; Ségolène Veau; Clémentine Fournier; Patrick Vourc'h; Patrick Emond; Paul Gordon; Pierre-François Pradat; Julien Praline; David Devos; Lydie Nadal-Desbarats; Christian R Andres
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

6.  Biomarker Discovery and Translation in Metabolomics.

Authors:  G A Nagana Gowda; D Raftery
Journal:  Curr Metabolomics       Date:  2013

Review 7.  Advances in cellular models to explore the pathophysiology of amyotrophic lateral sclerosis.

Authors:  C Veyrat-Durebex; P Corcia; A Dangoumau; F Laumonnier; E Piver; P H Gordon; C R Andres; P Vourc'h; H Blasco
Journal:  Mol Neurobiol       Date:  2013-11-07       Impact factor: 5.590

8.  Disruption of TCA Cycle and Glutamate Metabolism Identified by Metabolomics in an In Vitro Model of Amyotrophic Lateral Sclerosis.

Authors:  Charlotte Veyrat-Durebex; Philippe Corcia; Eric Piver; David Devos; Audrey Dangoumau; Flore Gouel; Patrick Vourc'h; Patrick Emond; Frédéric Laumonnier; Lydie Nadal-Desbarats; Paul H Gordon; Christian R Andres; Hélène Blasco
Journal:  Mol Neurobiol       Date:  2015-12-14       Impact factor: 5.590

9.  Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis.

Authors:  Kjetil Bjornevik; Zhongli Zhang; Éilis J O'Reilly; James D Berry; Clary B Clish; Amy Deik; Sarah Jeanfavre; Ikuko Kato; Rachel S Kelly; Laurence N Kolonel; Liming Liang; Loic Le Marchand; Marjorie L McCullough; Sabrina Paganoni; Kerry A Pierce; Michael A Schwarzschild; Aladdin H Shadyab; Jean Wactawski-Wende; Dong D Wang; Ying Wang; JoAnn E Manson; Alberto Ascherio
Journal:  Neurology       Date:  2019-03-29       Impact factor: 9.910

10.  C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis.

Authors:  Scott P Allen; Benjamin Hall; Ryan Woof; Laura Francis; Noemi Gatto; Allan C Shaw; Monika Myszczynska; Jordan Hemingway; Ian Coldicott; Amelia Willcock; Lucy Job; Rachel M Hughes; Camilla Boschian; Nadhim Bayatti; Paul R Heath; Oliver Bandmann; Heather Mortiboys; Laura Ferraiuolo; Pamela J Shaw
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.